-
After Teresa Levitch underwent successful chemotherapy and radiation for the cancer attacking her immune system, she believed her health problems were over.
-
Roche Holding AG’s Avastin failed to extend the survival of patients with deadly brain tumors in a study that found no advantage in using the drug as a first-line therapy against the cancer known as glioblastoma.
-
Bayer AG and Onyx Pharmaceuticals Inc.’s drug Nexavar gave thyroid cancer patients a five-month respite from their tumors getting worse in a study that will be used to request broader marketing approval for the medicine.
-
Results from Given Imaging Ltd.’s latest clinical study of a pill-sized camera used to identify colon cancer probably will help the Israeli manufacturer secure U.S. regulatory approval this year, Chief Executive Officer Homi Shamir said.
-
Angelina Jolie’s decision to have a double mastectomy is fueling debate among the thousands of women at risk of developing breast cancer who want to know how, if and when to have their breasts removed.
-
AstraZeneca Plc will move three experimental cancer treatments into late-stage development as generic competition for its best-selling drugs intensifies.
-
Roche Holding AG’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
-
Roche Holding AG, the world’s biggest maker of cancer drugs, won U.S. approval to sell a gene mutation test that can help doctors pinpoint patients’ likelihood to respond to a popular treatment for lung cancer.
-
Tanning beds would be required to warn young people of the dangers of skin cancer and face tighter oversight under a proposal from U.S. regulators.
-
An analysis of the most common uterine cancer suggests the disease should be reclassified into four categories that may help lead to more targeted treatments.
Rate this Page